MBIO - Rasio utang marang kapitalisasi buku mustangbio.com

Logo grafis Mustang Bio Corp (MBIO)

Mustang Bio, Inc. (MBIO) is protected by a patent barrier and exclusive licenses for gene therapy. The company's debt-to-book capitalization ratio demonstrates financial leverage dynamics, with the indicator standing at 0.00. While the scientific platform ensures global scalability of products, the current liquidity shortage and research costs are forcing the business to divest assets to cover operating expenses.

Mustang Bio Inc - Utang-utang marang kapitalisasi buku MBIO (periode 04.07.2022 - 28.10.2026)
Produk mawa merek mustangbio.com

Mustang Bio, Inc. (MBIO) gene therapy development is independent of market cycles but requires constant R&D funding. The 0.00 metric is calculated as the ratio of total liabilities to the book value of equity. This ratio determines the level of financial leverage and the risk of business insolvency. A decrease in this indicator minimizes the probability of bankruptcy, although it may limit the growth rate of returns. The historical trend of the debt-to-book capitalization ratio clearly demonstrates the stability of the company's capital structure.

Pesaing Mustang Bio, Inc.

Utang-utang marang kapitalisasi buku TEM (Tempus AI Inc)|qiagen.com - Utang-utang marang kapitalisasi buku|IONS: Rasio utang marang kapitalisasi buku|Repligen Corp (RGEN) - Utang marang nilai buku|RNA: Utang marang nilai buku|CRSP (CRISPR) - Utang-utang marang kapitalisasi buku|WGS: Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik ultragenyx.com (RARE)|Utang marang nilai buku Beam Therapeutics|Utang marang modal buku Sarepta Therapeutics (SRPT)|Utang-utang marang kapitalisasi buku TWST (Twist Bio)|10x - Utang-utang marang kapitalisasi buku|Intellia Therapeutics (NTLA) - Rasio utang marang kapitalisasi buku|STOK - Rasio utang marang nilai buku|Utang-utang marang kapitalisasi buku BLFS (BioLife Solutions)|Utang marang aset resik Wave Life Sciences Ltd|MAZE - Utang marang nilai buku|Rasio utang marang aset resik Sionna Corp|Utang-utang marang kapitalisasi buku Prime Medicine, Inc. (PRME)|Rasio utang marang kapitalisasi buku tayshagtx.com (TSHA)|Utang-utang marang kapitalisasi buku QURE|MeiraGTx Holdings - Utang-utang marang aset resik|RGNX (Regenxbio) - Rasio utang marang kapitalisasi buku|Solid Corp (SLDB) - Utang-utang marang nilai buku|Utang marang nilai buku Ocugen, Inc. OCGN|pacb.com (PACB) - Rasio utang marang aset resik|BNTC: Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik DSGN|Rasio utang marang kapitalisasi buku Rocket Pharmaceuticals Inc RCKT|Rasio utang marang nilai buku 4D Molecular Corp (FDMT)|Lexeo Therapeutics, Inc. - Utang-utang marang kapitalisasi buku|KRRO - Utang marang nilai buku|Utang marang nilai buku EDIT (Editas Medicine)|SLN: Utang-utang marang aset resik|PRQR (proqr.com) - Rasio utang marang kapitalisasi buku|Codexis (CDXS) - Utang marang nilai buku|Utang-utang marang kapitalisasi buku Sangamo Therapeutics|Rasio utang marang kapitalisasi buku Nautilus Biotechnology Inc|MGX (Metagenomi) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik DTIL (Precision BioSciences Inc.)|GBIO: Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Boundless Bio Inc BOLD|Exicure Corp (XCUR) - Utang-utang marang kapitalisasi buku|IMNN: Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku phiopharma.com|TransCode Therapeutics, Inc. (RNAZ) - Rasio utang marang nilai buku|BNGO (Bionano Genomics Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku APDN|Rasio utang marang kapitalisasi buku BLUE (bluebird bio, Inc.)|Utang marang nilai buku immunoprecise.com IPA|Utang marang nilai buku OMGA (Omega Therapeutics, Inc.)|Singular Genomics Systems, Inc. - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku RGLS (Regulus Therapeutics Inc)|Syros Pharmaceuticals, Inc (SYRS) - Utang-utang marang aset resik|TBIO - Utang marang nilai buku|traconpharma.com (TCON) - Utang marang modal buku|UBX (Unity Biotechnology, Inc.) - Utang-utang marang kapitalisasi buku